---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-075189"
form_type: "8-K"
ticker: "NTRA"
cik: "0001604821"
company_name: "Natera, Inc."
filed_at: "2025-08-07T23:59:59+00:00"
generated_at: "2026-05-17T17:37:16.066434+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Natera Q2 revenue up 32% to $546.6M; raises FY2025 revenue outlook by $80M

## Summary
- Total revenue $546.6M (+32.2% YoY); product revenue $544.4M (+32.3%).
- Oncology tests grew 50.6% to 188,800; total tests processed 853,100 (+12.2%).
- Achieved positive cash flow of ~$24.3M in Q2; cash and investments $1,016M.
- Net loss per diluted share ($0.74) vs ($0.30) in Q2 2024, impacted by $19.8M legal accruals.
- Raising 2025 revenue guidance to $2.02B-$2.10B from $1.94B-$2.02B; OpEx outlook unchanged.

## SEC filing metadata
- accession: 0001104659-25-075189
- form_type: 8-K
- ticker: NTRA
- cik: 0001604821
- company_name: Natera, Inc.
- filed_at: 2025-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1604821/000110465925075189/0001104659-25-075189-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1604821/000110465925075189/tm2522162d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-075189
- JSON: https://secwatch.observer/filing/0001104659-25-075189.json
- Plain text: https://secwatch.observer/filing/0001104659-25-075189.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.